GRP
VTGN icon

Global Retirement Partners’s VistaGen Therapeutics VTGN Stock Holding History

Global Retirement Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed -$5K – 1778
2021
Q3 		$5K Hold
67
– – ﹤0.01% 1645
2021
Q2 		$6K Buy
+67
New +$4.96K ﹤0.01% 1540

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Global Retirement Partners's VTGN Position: Q4 2021 in Review

Global Retirement Partners sold out of VistaGen Therapeutics (VTGN) in Q4 2021, closing a stake of 67 shares — an estimated $5K sold.

Global Retirement Partners first reported a position in VTGN in Q2 2021 and held it in 2 quarters. The position peaked at $6K in Q2 2021. 106 funds tracked by Wall St. Rank hold VTGN as of Q4 2021.

  • Global Retirement Partners reported no remaining VistaGen Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Global Retirement Partners sold 67 VistaGen Therapeutics shares in Q4 2021, an estimated $5K.
  • Global Retirement Partners first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 2 quarters.
  • Global Retirement Partners's VistaGen Therapeutics position peaked at $6K in Q2 2021.
  • 106 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2021.

Based on Global Retirement Partners's 13F filing for Q4 2021, filed 21 Jan 2022.